Intriguingly, there is conflicting evidence the intranasal administration of DClps producing high levels of IL-10 enhanced airway inflammation (34), and the intravenous infusion of DC10 failed to reverse the asthma phenotype in sensitized mice (35). Here, IL10 is linked to asthma.